9-acetoacetyl-carbazole | 49559-05-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 9-acetoacetyl-carbazole
• 英文别名: 9-Acetoacetyl-carbazol；1-Carbazol-9-ylbutane-1,3-dione
• CAS: 49559-05-9
• 化学式: C₁₆H₁₃NO₂
• 分子量: 251.285
• InChiKey: JVBLAODFNPHMGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  39.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  9-acetoacetyl-carbazole 在 硫酸 作用下， 生成 4-methyl-pyrido[3,2,1-jk]carbazol-6-one
  参考文献：
  名称：

  Perekalin; Lerner, Zhurnal Obshchei Khimii, 1951, vol. 21, p. 1995,1999; engl. Ausg. S. 2219, 2223

  摘要：

  DOI：
• 作为产物：
  描述：

  咔唑 、 3-氧代丁酰氯 在 丙酮 作用下， 生成 9-acetoacetyl-carbazole
  参考文献：
  名称：

  Perekalin; Lerner, Zhurnal Obshchei Khimii, 1951, vol. 21, p. 1995,1999; engl. Ausg. S. 2219, 2223

  摘要：

  DOI：

文献信息

• Acetoacetylamino compounds and a process of making same
  申请人：DURAND &

  公开号：US02776983A1

  公开（公告）日：1957-01-08

  The invention comprises the N-acetoacetyl derivative of 1-chloro-2-aminoanthraquinone, and the preparation thereof and of other acetoacetylaminoanthraquinones by heating aminoanthraquinones with diketene in the presence of 90-100 per cent (preferably glacial) acetic acid at 40-80 DEG C. (preferably 60-70 DEG C.). Examples describe the acetoacetylation of 1- and 2-aminoanthraquinone, 1- and 3-chloro-2-aminoanthraquinone and 1-amino - 5 - benzoylaminoanthraquinone, and the di-acetoacetylation of 1 : 5-diaminoanthraquinone. Additional starting materials specified are 1-amino-4-benzoylaminoanthraquinone, 1 - amino - 4 - phenylaminoanthraquinone and 1 : 4 - diaminoanthraquinone. Specification 429,982 is referred to.ALSO:The invention comprises N - acetoacetyl derivatives of 4-benzoylaminodiphenylamine, carbazole, 1-aminobenzene-4-sulphonic acid 21-thiazolylamide, and naphthosultam, and the preparation thereof and of other acetoacetyl-amino compounds by heating a primary or secondary aromatic amine, or a heterocyclic compound containing a secondary nitrogen atom in the heterocyclic nucleus, with diketene in the presence of 90-100 per cent (preferably glacial) acetic acid at 40-80 DEG C. (preferably 60-70 DEG C.). Examples describe the acetoacetylation of the four compounds specified above and of 1-aminobenzene-4-sulphonic acid morpholide and diphenylamine. Additional starting materials specified include benzidine naphthoquinone, 1-aminobenzene-4-sulphonic acid p-phenylanilide and dimethylamide, 4-aminodiphenylsulphone, and N-phenyl-1-and-2-naphthylamine. Specification 429,982 is referred to.

  本发明涉及1-氯-2-氨基蒽醌的N-乙酰乙酰衍生物，以及通过在90-100％（优选为冰醋酸）乙酸存在下，在40-80℃（优选为60-70℃）下加热氨基蒽醌和二酮烯制备其他乙酰乙酰氨基蒽醌和1-和2-氨基蒽醌、1-和3-氯-2-氨基蒽醌、1-氨基-5-苯甲酰氨基蒽醌的例子描述，并且对1:5-二氨基蒽醌进行了双乙酰乙酰化。此外，指定了其他起始材料，包括1-氨基-4-苯甲酰氨基蒽醌、1-氨基-4-苯基氨基蒽醌和1:4-二氨基蒽醌。参考专利规格书429,982。 此外，本发明还涉及4-苯甲酰氨基二苯胺、咔唑、1-氨基苯并-4-磺酸21-噻唑酰胺和萘磺酰胺的N-乙酰乙酰衍生物，以及通过在90-100％（优选为冰醋酸）乙酸存在下，在40-80℃（优选为60-70℃）下加热含有二级氮原子的芳香胺或杂环化合物，制备其他乙酰乙酰氨基化合物。例子描述了上述四种化合物和1-氨基苯并-4-磺酸吗啉酰和二苯胺的乙酰乙酰化，指定的其他起始材料包括苯二胺萘醌、1-氨基苯并-4-磺酸对苯基苯胺酰和二甲基酰胺、4-氨基二苯磺酮和N-苯基-1-和2-萘胺。参考专利规格书429,982。
• FULVENE AND FULVALENE ANALOGS AND THEIR USE IN TREATING CANCERS
  申请人：Arbiser Jack L.

  公开号：US20080275016A1

  公开（公告）日：2008-11-06

  Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are fulvene and/or fulvalene analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, as well as numerous inflammatory, degenerative and vascular diseases, including various ocular diseases. Representative fulvene and/or fulvalene analogs include fulvene and fulvalene analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function, at least, by inhibiting Nox or ROS. In some embodiments, the Nox is one that is selectively expressed in cancer cells over normal cells, or one that is expressed in higher amounts in cancer cells over normal cells. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.
• US8841276B2
  申请人：——

  公开号：US8841276B2

  公开（公告）日：2014-09-23
• [EN] COLD CURABLE RESIN COMPOSITION, CURING METHOD OF THE RESIN COMPOSITION AND CURED PRODUCT OF THE RESIN COMPOSITION<br/>[FR] COMPOSITION DE RESINE DURCISSANT A FROID, PROCEDE DE DURCISSEMENT DE LA COMPOSITION DE RESINE ET PRODUIT DURCI DE LA COMPOSITION DE RESINE
  申请人：DJK LAB INC

  公开号：WO2003082978A1

  公开（公告）日：2003-10-09

  An resin composition comprising an oligo(meth)acrylate having one or more (meth)acryloyl groups within one molecule, an allyl monomer of a saturated and/or unsaturated polybasic acid, and an acetoacetamide compound. The problem of reduction in curability at an ordinary temperature can be solved in a radical curable resin composition comprising an oligo(meth)acrylate diluted with an allyl monomer.
• [EN] FULVENE AND FULVALENE ANALOGS AND THEIR USE IN TREATING CANCERS<br/>[FR] ANALOGUES DE FULVÈNE ET FULVALÈNE ET LEUR UTILISATION DANS LE TRAITEMENT DES CANCERS
  申请人：UNIV EMORY

  公开号：WO2008137740A1

  公开（公告）日：2008-11-13

  [EN] Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are fulvene and/or fulvalene analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, as well as numerous inflammatory, degenerative and vascular diseases, including various ocular diseases. Representative fulvene and/or fulvalene analogs include fulvene and fulvalene analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function, at least, by inhibiting Nox or ROS. In some embodiments, the Nox is one that is selectively expressed in cancer cells over normal cells, or one that is expressed in higher amounts in cancer cells over normal cells. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.
  [FR] L'invention concerne des composés, des compositions pharmaceutiques contenant ces composés, et des procédés de préparation et d'utilisation de ceux-ci. Ces composés consistent en des analogues de fulvène et/ou fulvalène. Ces composés et ces compositions peuvent être utilisés pour traiter et/ou prévenir une grande variété de cancers, notamment les cancers résistant aux médicaments, ainsi que de nombreuses maladies inflammatoires, dégénératives et vasculaires, de même que diverses maladies oculaires. Les analogues représentatifs de fulvène et/ou fulvalène consistent en des analogues de fulvène et fulvalène de divers colorants, hormones, sucres, peptides, oligonucléotides, acides aminés, nucléotides, nucléosides, et polyols. Ces composés semblent fonctionner, au moins, par inhibition de Nox ou des ROS. Dans certains modes de réalisation, le Nox est celui qui est sélectivement exprimé dans des cellules cancéreuses plutôt que dans les cellules normales, ou celui qui est exprimé en plus grandes quantités dans les cellules cancéreuses que dans les cellules normales. Ainsi, les composés consistent en de nouveaux agents thérapeutiques d'une variété de cancers et d'autres maladies.